Clinical trials
Phase 2/3 trials in Mexico with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 2 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 6 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 30 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Asociación para Evitar la Ceguera en México | 3 |
| Instituto Nacional de Cancerologia de Mexico | 3 |
| Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 3 |
| LensAR Incorporated | 2 |
| Cidat, S.A. de C.V. | 1 |
| Coordinación de Investigación en Salud, Mexico | 1 |
| El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez | 1 |
| Grupo Medifarma, S. A. de C. V. | 1 |
| Hospital General Naval de Alta Especialidad - Escuela Medico Naval | 1 |
| Hospital General de Mexico | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| COVID-19 | 4 |
| Diabetes Mellitus, Type 2 | 3 |
| Acute Kidney Injury | 2 |
| Cataract | 2 |
| Diabetes Mellitus | 2 |
| Agnosia | 1 |
| Alveolitis, Extrinsic Allergic | 1 |
| Anorexia | 1 |
| Breast Neoplasms | 1 |
| Cachexia | 1 |
Trials
Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.